High-dose lymphoablative therapy (HDLT) with or without autologous stem-cell rescue for treatment of severe autoimmune diseases.
D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000401:mortality / Q000628:therapy*; D054598:Blue Cross Blue Shield Insurance Plans; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019458:Insurance Coverage; D013673:Technology Assessment, Biomedical; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide